News brief­ing: Al­ny­lam wins EC OK for its third drug, putting them out front on PH1; Big biotech VC Qim­ing clos­es out Fund VII with $1.2B

Al­ny­lam $AL­NY put out word to­day that the Eu­ro­pean Com­mis­sion has ap­proved its third drug, lumasir­an, for pri­ma­ry hy­per­ox­aluria type 1, bet­ter known as PH1. It will be mar­ket­ed as Oxlu­mo.

An ul­tra rare ge­net­ic con­di­tion, Al­ny­lam CEO John Maraganore says there are on­ly some 1,000 to 1,700 pa­tients in the US and Eu­rope at any par­tic­u­lar point. The pa­tients, most­ly kids, suf­fer from an over­pro­duc­tion of ox­alate in the liv­er that spurs the de­vel­op­ment of kid­ney stones, right through to end stage kid­ney dis­ease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.